Alpha-1 proteinase inhibitor (human) second generation is under clinical development by Kamada Pharmaceuticals and currently in Phase II for Alpha-1 Antitrypsin Deficiency (A1AD). According to GlobalData, Phase II drugs for Alpha-1 Antitrypsin Deficiency (A1AD) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Alpha-1 proteinase inhibitor (human) second generation’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Alpha-1 proteinase inhibitor (human) second generation overview

Alpha-1 proteinase inhibitor (human) is under development for the treatment of alpha- antitrypsin deficiency (inherited emphysema) and bronchiectasis. It is administered through inhalation using e-Flow based inhalation device. The drug candidate is a second generation AAT product. The development of drug candidate is based on e-Flow aerosol technology. It was also under development for cystic fibrosis.

Kamada Pharmaceuticals overview

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Kamada Pharmaceuticals (Kamada), is a biopharmaceutical company that develops, manufactures, and commercializes specialty proteins, specific immunoglobulins, and other prescription medicines. Its major products include respiratory, immunoglobins, critical care, and others. It also offers medicines for the treatment of cystic fibrosis, asthma, hemophilia, rabies, hepatitis B and other indications. Kamada’s pipeline products include intravenous and inhaled AAT protein and rabies. Its intravenous formulations are intended for Graft vs Host Disease (GVHD), type-1 diabetes, covid-19, and lung transplantation indications. The company distributes its products through a network of distributors in Brazil, Israel, Russia, India, and other countries in Eastern Europe, Latin America, and Asia regions. Kamada is headquartered in Rehovot, Israel.

For a complete picture of Alpha-1 proteinase inhibitor (human) second generation’s drug-specific PTSR and LoA scores, buy the report here.